News

News

We publish news of technology innovations, investment opportunities, together with updates from spin-out & start-up companies and licensees

Summit hits first milestone in Duchenne muscular dystrophy program

2nd December 2015
All News | Isis Spin-Outs & Start-Ups | Technology News

Nasdaq-listed Oxford spinout Summit Therapeutics has hit its first research milestone as part of a multiyear strategic alliance with the University of Oxford. The collaboration is focussed on developing future-generation utrophin modulators for the potential treatment of all patients with the progressive muscle wasting disorder Duchenne Muscular Dystrophy.

Read more

Extension of strategic alliance with Summit

17th November 2015
All News | Isis Spin-Outs & Start-Ups | Technology News

Summit Therapeutics and Oxford have announced a multi-year extension of their strategic alliance for the development of utrophin modulators to treat Duchenne Muscular Dystrophy.

Read more

© Isis Innovation